Edition:
India

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

0.90USD
18 Jun 2019
Change (% chg)

$0.01 (+1.12%)
Prev Close
$0.89
Open
$0.90
Day's High
$0.91
Day's Low
$0.85
Volume
3,130
Avg. Vol
41,271
52-wk High
$6.17
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Aileron Therapeutics Updated Information On Design, Anticipated Timing Of Data From Its Ongoing Alrn-6924 Trials
Thursday, 6 Jun 2019 

June 5 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS - UPDATED INFORMATION ON DESIGN, ANTICIPATED TIMING OF DATA FROM ITS ONGOING, PLANNED CLINICAL ALRN-6924 TRIALS.AILERON THERAPEUTICS INC - CONDUCTING A PHASE 2A CLINICAL TRIAL OF COMBINATION OF ALRN-6924 AND PALBOCICLIB (IBRANCE), MARKETED BY PFIZER.AILERON THERAPEUTICS INC - TO HAVE FINAL DATA FROM ALL 25 PATIENTS IN ALRN-6924 TRIAL IN Q2 OF 2020.AILERON THERAPEUTICS INC - PLANS TO DISCLOSE DATA FROM PHASE 1B PORTION OF MYELOPRESERVATION TRIAL IN Q2 OF 2020.  Full Article

Aileron Therapeutics Reports Q1 Loss Per Share Of $0.49
Thursday, 9 May 2019 

May 8 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.  Full Article

Aileron Therapeutics Appoints Jeffrey Bailey As Chairman Of Board
Monday, 19 Mar 2018 

March 19 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS APPOINTS JEFFREY A. BAILEY TO ITS BOARD OF DIRECTORS.AILERON THERAPEUTICS INC - ‍APPOINTMENT OF JEFFREY BAILEY AS CHAIRMAN OF ITS BOARD​.AILERON THERAPEUTICS INC - ‍BAILEY REPLACES SCOTT KAPNICK AS CHAIRMAN​.AILERON THERAPEUTICS INC - ‍KAPNICK WILL REMAIN A DIRECTOR​.  Full Article

Aileron Therapeutics posts Q3 loss of $0.45 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.45.Q3 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Cash, cash equivalents and investments as of Sept. 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016​.Qtrly ‍non-gaap net loss per share attributable to common stockholders $0.43​.  Full Article

Aileron Therapeutics reports second quarter 2017 financial results
Friday, 11 Aug 2017 

Aug 10 (Reuters) - Aileron Therapeutics Inc :Aileron Therapeutics reports second quarter 2017 financial results.Q2 loss per share $10.98.Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Aileron Therapeutics shares open 8.3 pct below IPO price in debut
Thursday, 29 Jun 2017 

June 29 (Reuters) - :Aileron therapeutics inc shares open at $13.75 in debut on the nasdaq versus ipo price of $15.00 per share.  Full Article

Aileron Therapeutics prices IPO at $15 per share
Thursday, 29 Jun 2017 

June 29 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics announces pricing of initial public offering.Aileron therapeutics-announced pricing of initial public offering of 3.7 million shares of common stock at a public offering price of $15.00 per share.  Full Article